Alkem Laboratories settles with 31.5% premium on debut

At Rs 1,381.45 on BSE

Shares of Alkem Laboratories settled at Rs 1,381.45 on BSE, a steep premium of 31.56% over the initial public offer price of Rs 1,050 per share.

Meanwhile, the S&P BSE Sensex rose 259.65 points or 1.01% to settle at 25,850.30.

The stock debuted at Rs 1,380 on BSE, a premium of 31.42% compared with its initial public offer (IPO) price. The stock hit a high of Rs 1,410 and a low of Rs 1,355.40 in intraday trade. On BSE, 24.38 lakh shares were traded on the counter during the day.

Alkem Laboratories IPO closed on 10 December 2015. It was subscribed 44.29 times with good response from non-institutional investors and qualified institutional buyers (QIBs). A discount of Rs 100 per equity share to the issue price of Rs 1,050 was offered to eligible employees.

Earlier, Alkem Laboratories had raised Rs 395.46 crore by selling 37.66 lakh shares to a total of 25 anchor investors. The shares were allotted to the anchor investors at Rs 1,050 per share, the top end of the Rs 1,020-Rs 1,050 per share price band for the IPO.

On a consolidated basis, Alkem Laboratories reported profit after tax of Rs 431.29 crore on total sales of Rs 2570.13 crore in the half year ended 30 September 2015.

Alkem Laboratories is the fifth largest pharmaceutical company in India by domestic sales. The developer, manufacturer and seller of pharmaceutical and neutraceutical products including branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals has 14 manufacturing locations in India and two in the US. Five of these plants are approved by the US Food and Drug Administration.

Powered by Capital Market - Live News